# National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

> **NCT02664935** · PHASE2 · COMPLETED · sponsor: **University of Birmingham** · enrollment: 423 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer
- Carcinoma, Squamous Cell
- Adenocarcinoma

## Interventions

- **DRUG:** AZD4547
- **DRUG:** Vistusertib
- **DRUG:** Palbociclib
- **DRUG:** Crizotinib
- **DRUG:** Selumetinib
- **DRUG:** Docetaxel
- **DRUG:** AZD5363
- **DRUG:** Osimertinib
- **DRUG:** Durvalumab
- **DRUG:** Sitravatinib
- **DRUG:** AZD6738

## Key facts

- **NCT ID:** NCT02664935
- **Lead sponsor:** University of Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-13
- **Primary completion:** 2023-11-29
- **Final completion:** 2023-11-29
- **Target enrollment:** 423 (ACTUAL)
- **Last updated:** 2026-04-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02664935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02664935, "National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02664935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*